Skip to main content

Table 5 Analysis of FA in triglyceride and phospholipid fractions

From: Modulation of endothelial cell integrity and inflammatory activation by commercial lipid emulsions

 

(a) Triglyceride

 

(b) Phospholipid

Fatty acid

Vehicle

OO

SO

FO

Fatty acid

Vehicle

OO

SO

FO

C8:0

0.14 ± 0.05a

0.06 ± 0.00b

0.15 ± 0.08a

0.10 ± 0.04a

C8:0

0.13 ± 0.04a

0.04 ± 0.00b

0.11 ± 0.03a

0.16 ± 0.05a

C10:0

0.05 ± 0.01a

0.03 ± 0.01a

0.09 ± 0.01a

0.06 ± 0.03a

C10:0

0.07 ± 0.01a

0.03 ± 0.00a

0.05 ± 0.01a

0.10 ± 0.05a

C12:0

0.14 ± 0.02a

0.07 ± 0.02b

0.21 ± 0.08a

0.03 ± 0.01b

C12:0

0.15 ± 0.06a

0.04 ± 0.01b

0.06 ± 0.00b

0.05 ± 0.04b

C14:0

0.42 ± 0.04a

0.41 ± 0.05a

0.42 ± 0.02a

0.81 ± 0.07b

C14:0

3.36 ± 0.30a

0.62 ± 0.25b

0.82 ± 0.10b

0.92 ± 0.37b

C16:0

1.19 ± 0.42a

12.98 ± 1.67b

8.06 ± 0.92c

12.92 ± 1.74b

C16:0

25.93 ± 1.65a

14.41 ± 1.74b

17.97 ± 1.83b

11.15 ± 1.60b

C16:1n7

0.17 ± 0.06a

0.67 ± 0.07b

0.33 ± 0.03c

0.48 ± 0.08d

C16:1n7

3.69 ± 0.20a

0.72 ± 0.02b

0.72 ± 0.10b

0.43 ± 0.05c

C18:0

0.54 ± 0.15a

3.47 ± 0.42b

2.97 ± 0.30b

3.24 ± 0.39b

C18:0

15.79 ± 0.70a

7.43 ± 1.51b

10.93 ± 1.01b

5.99 ± 1.40b

C18:1n-9

0.85 ± 0.32a

19.41 ± 2.31b

8.50 ± 0.91c

22.12 ± 3.65b

C18:1n-9

20.82 ± 1.09a

11.56 ± 1.14b

12.22 ± 1.30b

10.26 ± 2.78b

C18:1 n-7

0.19 ± 0.07a

1.05 ± 0.24b

0.51 ± 0.06c

1.17 ± 0.17b

C18:1 n-7

8.16 ± 0.40a

1.69 ± 0.12b

1.92 ± 0.21b

1.21 ± 0.18b

C18:2n-6

0.70 ± 0.99a

6.07 ± 0.82b

7.54 ± 1.01b

7.53 ± 1.31b

C18:2n-6

1.39 ± 0.05a

4.19 ± 0.51b

6.66 ± 0.69c

2.98 ± 0.54b

C18:3n-3

N/D

0.98 ± 0.17a

0.51 ± 0.06b

0.17 ± 0.03c

C18:3n-3

0.15 ± 0.02a

0.32 ± 0.04b

0.31 ± 0.04b

0.11 ± 0.03a

C18:3n-6

N/D

N/D

0.29 ± 0.05a

0.08 ± 0.01b

C18:3n-6

0.05 ± 0.02a

0.04 ± 0.01a

0.08 ± 0.02a

0.03 ± 0.01a

C20:0

N/D

N/D

N/D

N/D

C20:0

0.10 ± 0.00a

0.05 ± 0.02b

0.05 ± 0.02b

0.06 ± 0.02b

C20:4n-6

N/D

4.02 ± 0.49a

3.80 ± 0.51a

4.96 ± 0.76a

C20:4n-6

9.74 ± 0.16a

4.75 ± 0.43b

7.00 ± 0.82c

3.54 ± 0.59b

C20:5n-3

N/D

N/D

0.15 ± 0.02a

2.45 ± 0.40b

C20:5n-3

0.12 ± 0.01a

0.06 ± 0.01b

0.14 ± 0.04a

0.66 ± 0.09c

C22:0

0.13 ± 0.02

N/D

N/D

N/D

C22:0

0.22 ± 0.03a

0.19 ± 0.13a

0.12 ± 0.02b

0.11 ± 0.02b

C22:5n-6

N/D

0.45 ± 0.07a

0.25 ± 0.01b

0.78 ± 0.15a

C22:5n-6

1.28 ± 0.03a

0.71 ± 0.04b

0.70 ± 0.08b

0.44 ± 0.06c

C22:5n-3

N/D

0.20 ± 0.03a

0.35 ± 0.05b

0.82 ± 0.32c

C22:5n-3

1.62 ± 0.04a

0.35 ± 0.02b

0.71 ± 0.09c

0.32 ± 0.06b

C24:0

N/D

N/D

N/D

N/D

C24:0

0.30 ± 0.03a

0.07 ± 0.01b

0.12 ± 0.01c

0.08 ± 0.01b

C22:6n-3

N/D

1.28 ± 0.17a

2.00 ± 0.31a,b

2.82 ± 0.54b,c

C22:6n-3

2.26 ± 0.07a

1.60 ± 0.14b

3.18 ± 0.31a

0.84 ± 0.24c

SFA

2.60 ± 0.72a

17.01 ± 2.17b

11.90 ± 1.41c

17.16 ± 2.27b

SFA

46.05 ± 2.82a

22.88 ± 3.66b

30.21 ± 3.04c

18.64 ± 3.57b

MUFA

1.21 ± 0.46a

21.13 ± 2.62b

9.34 ± 1.00c

23.77 ± 3.90b

MUFA

32.67 ± 1.69a

13.9 ± 61.28b

14.86 ± 1.61b

11.90 ± 3.01b

n-6 PUFA

0.70 ± 0.99a

10.55 ± 1.39b

11.88 ± 1.57b

13.35 ± 2.24b

n-6 PUFA

12.45 ± 0.25a

9.68 ± 0.98b

14.44 ± 1.60a

6.99 ± 1.20c

n-3 PUFA

N/D

2.45 ± 0.37a

3.01 ± 0.43a

6.27 ± 1.28b

n-3 PUFA

4.15 ± 0.15a

2.33 ± 0.20b

4.35 ± 0.47a

1.92 ± 0.42b

TOTAL

4.52 ± 2.18a

51.14 ± 6.54b

36.14 ± 4.42c

60.55 ± 9.69b

TOTAL

95.32 ± 4.91a

48.86 ± 6.12b

63.86 ± 6.72c

39.45 ± 8.20b

  1. HAECs were supplemented with lipid emulsions (1%) for 24 hours under standard tissue culture conditions prior to analysis. Triglycerides (a) and Phospholipids (b) were resolved using thin layer chromatography and extracted as described in the methods. An “ND” indicates the lack of fatty acid detection. Results are expressed as the mean (wt%) ± SD of three experiments. One-way ANOVA with Tukey’s post hoc test using SPSS Statistics 20 software was performed to test differences between groups. The numbers with different letters represent a statistically significant difference p < 0.05.
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X